ExploreWatchlistsPricing
  1. JP-listed companies
  2. StemRIM Inc.
  3. Financials
  4. EBITDA

StemRIM Inc. (4599)

Market cap
¥19.3B
P/E ratio
StemRim develops regenerative induction pharmaceuticals that activate patients' own stem cells to repair damaged tissues using peptide-based drugs like Ledasemdide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Jul 31, 2025-1,922-5.40%
Jul 31, 2024-2,032-1168.34%
Jul 31, 2023190-109.85%
Jul 31, 2022-1,931+251.04%
Jul 31, 2021-550-229.92%
Jul 31, 2020423-158.39%
Jul 31, 2019-725+93.89%
Jul 31, 2018-374

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat